



## Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update

October 24, 2023

WARMINSTER, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its third quarter 2023 financial results and corporate update for Tuesday, November 7, 2023. The schedule for the press release and conference call/webcast are as follows:

- Q3/2023 Press Release: Tuesday, November 7, 2023 at 7:30 a.m. ET
- Q3/2023 Conference Call/Webcast: Tuesday, November 7, 2023 at 8:45 a.m. ET

To dial-in for the conference call by phone, please register using the following link: [Registration Link](#). A live webcast of the conference call can be accessed through the Investors section of Arbutus' website at [www.arbutusbio.com](http://www.arbutusbio.com).

An archived webcast will be available on the Arbutus website after the event.

### **About Arbutus**

Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran is the only RNAi that has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in two Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. We are also exploring oncology applications for our internal PD-L1 portfolio. For more information, visit [www.arbutusbio.com](http://www.arbutusbio.com).

### **Contact Information**

#### **Investors and Media**

Lisa M. Caperelli  
Vice President, Investor Relations  
Phone: 215-206-1822  
Email: [lcaperelli@arbutusbio.com](mailto:lcaperelli@arbutusbio.com)